Drug Trial Radar · NCT00117052
SENSOR: Study to Investigate Cinacalcet Treatment in Haemodialysis Patients With Secondary Hyperparathyroidism
Last checked: Nov 20, 2026Latest source record: May 23, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
673
Actual
Start
Sep 2004
Primary completion
Nov 2005
Study completion Feb 2006
Sponsor
- Lead sponsor
- AmgenAmgen (AMGN)
- Sponsor type
- Industry
- First posted
- Jul 4, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to demonstrate that the efficacy of cinacalcet when co-administered with the first meal after dialysis is comparable (non-inferior) to the efficacy of cinacalcet when administered during the dialysis study visit.
Conditions
- Secondary Hyperparathyroidism
- End Stage Renal Disease
Interventions
cinacalcetDrug
All eligible subjects were assigned to receive once daily oral doses of cinacalcet, but were randomised in a 1:1 ratio to receive the drug either with the first meal after dialysis or during the dialysis visit on dialysis days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of subjects with PTH less than or equal to 300pg/mLTime frame: 21 week dose optimisation phase
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.